nadofaragene firadenovec

AXP000143.2 · Viral vector gene therapy

Platform
adenovirus (Ad5, non-replicating, with Syn3 excipient)
Targets
IFNA2
Originator
Schering-Plough / Canji
Sponsor
Ferring Pharmaceuticals

Names

NameTypeSource
nadofaragene firadenovecpreferred name, INNcurator, ncit
Adstiladrinbrandfda
nadofaragene firadenovec-vncgUSANfda
rAd-IFN/Syn3codencit
SCH 721015former codencit
TR-002 ambiguousformer codencit
Instiladrinformer namencit

Virus

Role
In vivo gene transfer
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5
Replication
non replicating
Modifications
non-replicating adenoviral vector carrying the human interferon alfa-2b gene; instilled with the Syn3 excipient
Transgenes
IFNA2
Route
intravesical
Source
evidence

Cross-references

NCI Thesaurus
C71011
Wikidata
Q115779373
FDA UNII
0OOS09O1FH

Approvals

AgencyRegionDateStatusBrandIndicationSource
FDAUS2022-12-16approvedAdstiladrinHigh-grade, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumourssource

Clinical trials (16)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07332351Neoadjuvant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA TrialNot yet recruitingPhase 22026-12-012027-06-0124Muscle Invasive Bladder Urothelial Carcinoma; Stage II Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8
NCT06668493Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal PelvisRecruitingPhase 1/22025-06-122029-11-3020Low-grade Upper Tract Urothelial Carcinoma
NCT06929286A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)RecruitingPhase 32025-04-112028-04125Non-Muscle Invasive Bladder Cancer
NCT06545955A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder CancerRecruitingPhase 32024-10-012028-06-30250Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
NCT06510374Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder CancerRecruitingPhase 32024-10-012028-09-30454Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06390111A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.WithdrawnPhase 42024-06-172026-07-310Bladder Cancer; CIS; Ta/T1
NCT06026332ADSTILADRIN Early Utilization and Outcomes in the Real World SettingTerminated2023-09-152026-01-15202Bladder Cancer
NCT05704244Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)Active not recruitingPhase 32022-12-212029-11-3025Bladder Cancer
NCT03710876Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural MesotheliomaCompletedPhase 32019-01-212024-03-2953Malignant Pleural Mesothelioma
NCT02773849ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)CompletedPhase 32016-09-192019-05-24157Superficial Bladder Cancer
NCT01687244Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder CancerCompletedPhase 22012-092015-1040Superficial Bladder Cancer
NCT011627851B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder CancerCompletedPhase 12011-042016-117Bladder Cancer
NCT01119664Combination Gene Transfer and ChemotherapyCompletedPhase 12010-04-272013-10-1440Mesothelioma
NCT01212367Intrapleural Gene Transfer for Pleural MesotheliomaCompletedPhase 12009-022015-0513Malignant Pleural Mesothelioma
NCT00536588A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)CompletedPhase 12006-092009-0817Bladder Neoplasms
NCT00299962Gene Therapy for Pleural MalignanciesCompletedPhase 12006-032008-0517Metastatic Pleural Effusions; Pleural Mesothelioma
Unconfirmed matches (1)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT07189195TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic AdenocarcinomaRecruitingPhase 12025-11-072029-11-0752Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Refractory Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Malignant Solid Neoplasm; Unresectable Pancreatic Adenocarcinomaintervention named: TR-002

Recent changes

SeenTrialChangeDetailTitle
2026-11-15NCT07332351completion slipped2027-01-01 → 2027-06-01Neoadjuvant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial
2026-11-15NCT07332351enrolment33 (ESTIMATED) → 24 (ESTIMATED)Neoadjuvant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial
2026-11-15NCT07332351intervention added– → ["Enfortumab Vedotin", "Pembrolizumab"]Neoadjuvant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41253655Real-world outcomes of nadofaragene firadenovec for BCG-unresponsive non-muscle-invasive bladder cancer: A multicenter experience.Urologic oncology2026name in title: nadofaragene firadenovec
PMID 39406613Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer Treated with Nadofaragene Firadenovec.European urology oncology2025name in title: nadofaragene firadenovec
PMID 40194933Safety of nadofaragene firadenovec-vncg: review of data from phase 2 and phase 3 studies.The Canadian journal of urology2025cited by trial NCT01687244
PMID 38556413Radiotherapy Combined with a Radiosensitizer for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Carcinoma In Situ Bladder Cancer: An Open-label, Single-arm, Multicenter, Phase 2 European Organisation for Research and Treatment of Cancer Trial.European urology oncology2024name in abstract: nadofaragene firadenovec
PMID 38704840Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.The Journal of urology2024cited by trial NCT02773849
PMID 34933753Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.European urology2022name in title: nadofaragene firadenovec
PMID 33253641Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.The Lancet. Oncology2021cited by trial NCT02773849
PMID 28834453Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2017cited by trial NCT01687244
PMID 23507396Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.The Journal of urology2013cited by trial NCT00536588
PMID 21642245A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma.American journal of respiratory and critical care medicine2011cited by trial NCT01212367

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41422765Urothelial Carcinoma In Situ: Advances in Diagnosis and Management.Clinical genitourinary cancer2026name in abstract: nadofaragene firadenovec
PMID 41555169[Evolving Pharmacotherapy for Bladder Cancer-From Non-Muscle-Invasive to Metastatic Disease-Development of Novel Therapies for BCG-Unresponsive NMIBC].Gan to kagaku ryoho. Cancer & chemotherapy2026name in abstract: nadofaragene firadenovec
PMID 41647170Current use of pre-clinical models for evaluation of human adenovirus-based cancer therapeutics.Molecular therapy. Oncology2026name in abstract: Adstiladrin
PMID 41749876Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer.Cancers2026name in abstract: nadofaragene firadenovec
PMID 41780023Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin immunotherapy.Journal of medical economics2026name in title: nadofaragene firadenovec
PMID 41825577Advances in intravesical therapy for non-muscle-invasive bladder cancer.Critical reviews in oncology/hematology2026name in abstract: nadofaragene firadenovec
PMID 42012856Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United States.Journal of medical economics2026name in abstract: nadofaragene firadenovec
PMID 42216552Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer.Frontiers in bioscience (Landmark edition)2026name in abstract: nadofaragene firadenovec
PMID 42248643Non-replicating adenoviral vectors for cancer gene therapy.Advances in cancer research2026name in abstract: Adstiladrin
PMID 42260513Immunotherapy in bladder cancer: a systematic review of clinical trials and therapeutic advances.BMC urology2026name in abstract: nadofaragene firadenovec
PMID 42293862Analysis of real-world re-induction outcomes with nadofaragene firadenovec in patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer.Translational andrology and urology2026name in title: nadofaragene firadenovec
PMID 42362299Emerging Intravesical Therapies for Non-Muscle-Invasive Bladder Cancer.The Urologic clinics of North America2026name in abstract: nadofaragene firadenovec
PMID 42599325Deep learning-based automated identification of papillary bladder cancer from endoscopic still images using SE-ResNeXt-50.World journal of urology2026name in abstract: nadofaragene firadenovec
PMID 42702389[Advances in intravesical therapy for non-muscle-invasive bladder cancer].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2026name in abstract: nadofaragene firadenovec
PMID 42729065Re-induction with nadofaragene firadenovec: a fragile signal that should not influence clinical practice.Translational andrology and urology2026name in title: nadofaragene firadenovec
PMID 42792838Molecular Classifications and Candidate Biomarkers for Personalizing BCG Therapy in Non-Muscle-Invasive Bladder Cancer.Biomedicines2026name in abstract: nadofaragene firadenovec
PMID 42798234Trial design drives outcomes: harmonising efficacy across BCG-unresponsive bladder carcinoma in situ trials.BJU international2026name in abstract: nadofaragene firadenovec
PMID 42823172Complete Response Durability After TAR-200 and Nadofaragene Firadenovec in BCG-unresponsive Bladder CIS.Anticancer research2026name in title: nadofaragene firadenovec
PMID 42881230Combination therapy for BCG-unresponsive non-muscle-invasive bladder cancer: biological rationale and ongoing clinical strategies.Nature reviews. Urology2026name in abstract: nadofaragene firadenovec
PMID 42967132Bladder-Sparing Therapies for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ: An Upper and a Lower Response Group With an Unstable Boundary.Cureus2026name in abstract: nadofaragene firadenovec
PMID 42991509Defining safe bladder preservation in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: beyond complete response.Frontiers in immunology2026name in abstract: nadofaragene firadenovec
PMID 39376040Novel intravesical therapies and delivery systems for the management of bladder cancer.Current opinion in urology2025name in abstract: nadofaragene firadenovec
PMID 39550339Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group.European urology oncology2025name in abstract: nadofaragene firadenovec
PMID 39705065FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research2025name in title: nadofaragene firadenovec-vncg
PMID 39779686Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer.Expert opinion on biological therapy2025name in abstract: nadofaragene firadenovec
PMID 39933135New Treatment Options for Non-Muscle-Invasive Bladder Cancer.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting2025name in abstract: nadofaragene firadenovec
PMID 39962875Practical use of nadofaragene firadenovec-vncg for pharmacists.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners2025name in title: nadofaragene firadenovec-vncg
PMID 39976835Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer.Current oncology reports2025name in abstract: nadofaragene firadenovec
PMID 40396643Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer, a study with 5-year follow-up: a plain language summary.Future oncology (London, England)2025name in title: nadofaragene firadenovec
PMID 40569326Use of Rectal Diazepam to Prevent Bladder Spasms and Leakage of Medication During Intravesical Administration of Nadofaragene Firadenovec for Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer.The Journal of urology2025name in title: nadofaragene firadenovec
PMID 40584211Emerging bladder-sparing treatments for high risk non-muscle invasive bladder cancer.Bladder cancer (Amsterdam, Netherlands)2025name in abstract: nadofaragene firadenovec
PMID 40635630Intravesical interferon-α2b gene therapy with nadofaragene firadenovec-vncg: a contemporary review.Future oncology (London, England)2025name in title: nadofaragene firadenovec-vncg
PMID 40697667Advancements in bladder cancer immunotherapy: a focus on intravesical approaches.Frontiers in pharmacology2025name in abstract: nadofaragene firadenovec
PMID 40852908Outcomes of Reinduction With Nadofaragene Firadenovec.The Journal of urology2025name in title: nadofaragene firadenovec
PMID 40932192[INNOVATIONS IN THERAPIES FOR BACILLUS CALMETTE-GUERIN (BCG) FAILURE NON-MUSCLE INVASIVE PATIENTS].Harefuah2025name in abstract: nadofaragene firadenovec
PMID 40948378Mechanisms, Clinical Trials, and New Treatments for BCG-Unresponsive in Nonmuscle Invasive Bladder Cancer.Cancer medicine2025name in abstract: nadofaragene firadenovec
PMID 40970394Gene-mediated therapy for BCG-unresponsive nonmuscle-invasive bladder cancer: mechanisms, clinical evidence, and practical implementation.Current opinion in urology2025name in abstract: nadofaragene firadenovec
PMID 41230142Pharmacotherapy for bladder spasm and irritative lower urinary tract symptoms associated with intravesical therapy for bladder cancer: a review of available evidence.Translational andrology and urology2025name in abstract: nadofaragene firadenovec
PMID 41300998Gene Therapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: Current Evidence and Future Directions.Cancers2025name in abstract: nadofaragene firadenovec
PMID 41396440A systematic review of gene-mediated therapy in BCG-unresponsive NMIBC: emerging evidence and future perspectives.World journal of urology2025name in abstract: nadofaragene firadenovec
PMID 41425090Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies.Frontiers in cell and developmental biology2025name in abstract: nadofaragene firadenovec
PMID 41496691A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania.Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica2025name in abstract: nadofaragene firadenovec
PMID 38559556Mechanism of action of nadofaragene firadenovec-vncg.Frontiers in oncology2024name in title: nadofaragene firadenovec-vncg
PMID 38611044Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.Cancers2024name in abstract: nadofaragene firadenovec
PMID 38849286Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non-muscle-invasive Bladder Cancer.European urology oncology2024name in abstract: nadofaragene firadenovec
PMID 38861054An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer.Expert opinion on biological therapy2024name in title: nadofaragene firadenovec-vncg
PMID 38886756Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment.Journal of experimental & clinical cancer research : CR2024name in abstract: nadofaragene firadenovec
PMID 38895918Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.The Journal of urology2024name in title: nadofaragene firadenovec
PMID 38912644Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.The Journal of urology2024name in title: nadofaragene firadenovec
PMID 38968037Reply: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.The Journal of urology2024name in title: nadofaragene firadenovec
PMID 39131870The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward.Bladder cancer (Amsterdam, Netherlands)2024name in title: nadofaragene firadenovec
PMID 39183090Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection.European urology2024name in abstract: nadofaragene firadenovec
PMID 39254130Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.The Journal of urology2024name in title: nadofaragene firadenovec
PMID 39315392Clinical use of nadofaragene firadenovec-vncg.Therapeutic advances in urology2024name in title: nadofaragene firadenovec-vncg
PMID 39339191Recent Advances in Drug Delivery Strategies for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Brief Review from 2018 to 2024.Pharmaceutics2024name in abstract: Adstiladrin
PMID 39552770Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC): Current Guidance and Experience from Clinical Practice.Research and reports in urology2024name in abstract: nadofaragene firadenovec
PMID 39559365Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon α gene therapy in a murine bladder cancer model.Frontiers in immunology2024name in abstract: nadofaragene firadenovec
PMID 36529422Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guérin Immunotherapy Unresponsive Non-Muscle Invasive Bladder Cancer.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2023name in title: nadofaragene firadenovec
PMID 36856952Nadofaragene Firadenovec: First Approval.Drugs2023name in title: nadofaragene firadenovec
PMID 36877284In brief: Adstiladrin - a gene therapy for bladder cancer.The Medical letter on drugs and therapeutics2023name in title: Adstiladrin
PMID 37269456Correction to: Nadofaragene Firadenovec: First Approval.Drugs2023name in title: nadofaragene firadenovec
PMID 37705979Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval.Frontiers in immunology2023name in title: nadofaragene firadenovec
PMID 38037752Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.Cancer medicine2023name in abstract: nadofaragene firadenovec-vncg
PMID 38993180New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer.Bladder cancer (Amsterdam, Netherlands)2023name in abstract: nadofaragene firadenovec
PMID 40778028Nadofaragene firadenovec: a breakthrough in the field of bladder oncology.Frontiers in urology2023name in title: nadofaragene firadenovec
PMID 35086977Emerging treatment options for bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.Current opinion in supportive and palliative care2022name in abstract: nadofaragene firadenovec
PMID 35158964From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC).Cancers2022name in abstract: nadofaragene firadenovec
PMID 35172349[Adjuvant instillation therapy for non-muscle invasive bladder cancer - beyond BCG and mitomycin C].Aktuelle Urologie2022name in abstract: nadofaragene firadenovec
PMID 35383434Do we have enough evidence for approval of nadofaragene firadenovec?Minerva urology and nephrology2022name in title: nadofaragene firadenovec
PMID 35634893Emerging treatment landscape of non-muscle invasive bladder cancer.Expert opinion on biological therapy2022name in abstract: nadofaragene firadenovec
PMID 36051251Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments.Archives of pharmacology and therapeutics2022name in abstract: nadofaragene firadenovec
PMID 33253640Nadofaragene firadenovec: a new gold standard for BCG-unresponsive bladder cancer?The Lancet. Oncology2021name in title: nadofaragene firadenovec
PMID 33551296Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial.European urology2021name in title: nadofaragene firadenovec
PMID 33622578Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial.European urology2021name in title: nadofaragene firadenovec
PMID 33742981The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer.Current opinion in urology2021name in abstract: nadofaragene firadenovec
PMID 33958148Current Therapy and Emerging Intravesical Agents to Treat Non-Muscle Invasive Bladder Cancer.Hematology/oncology clinics of North America2021name in abstract: nadofaragene firadenovec
PMID 34057394The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer.Journal of managed care & specialty pharmacy2021name in title: nadofaragene firadenovec
PMID 34709440[Bacillus Calmette-Guérin (BCG) and alternatives : Drug treatment of high-risk non-muscle invasive bladder cancer].Der Urologe. Ausg. A2021name in abstract: nadofaragene firadenovec
PMID 34938855Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance.Molecular therapy oncolytics2021name in abstract: nadofaragene firadenovec
PMID 32304379Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?Current opinion in urology2020name in abstract: rAd-IFN/Syn3
PMID 32427633Bladder sparing landscape for bacillus Calmette-Guérin unresponsive bladder cancer.Current opinion in urology2020name in abstract: Adstiladrin
PMID 30357541Current Clinical Trials in Non-muscle Invasive Bladder Cancer.Current urology reports2018name in abstract: nadofaragene firadenovec
PMID 21900961Toxicity and exposure of an adenovirus containing human interferon alpha-2b following intracystic administration in cynomolgus monkeys.Gene therapy2012name in abstract: SCH 721015
PMID 17692556Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer.Cytokine & growth factor reviews2007name in abstract: rAd-IFN/Syn3
PMID 15992886Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens.Urology2005name in abstract: rAd-IFN/Syn3

NIH grants

ProjectTitleOrganisationPIYearsLinked by
P01CA296429Project 3: Identifying Molecular Vulnerabilities to Improve Interferon Gene Therapy in Bladder CancerUNIVERSITY OF TX MD ANDERSON CAN CTRDINNEY, COLIN P.N.2025–2026name in abstract: nadofaragene firadenovec

Notes

FDA approved 16 December 2022 (BLA 125700) as Adstiladrin, the first gene therapy for bladder cancer; proper name nadofaragene firadenovec-vncg. Given intravesically with the polyamide surfactant Syn3, which is part of the product rather than a separate agent. Earlier codes SCH 721015 (Schering-Plough) and TR-002 (FKD Therapies).

How to cite

nadofaragene firadenovec (AXP000143.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000143.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.